Latest news and press releases about Bone Biologics Corporation (BBLG): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth.
Price
| Price | $0.54 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.25 |
| EV / EBITDA | 1.38 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -57.85% |
| Return on Invested Capital | -78.01% |
| Return on Assets | -65.16% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BDRX · DHAI · GCTK · HSCS · INM · MOVE · NAOV
Explore sector: Healthcare · Biotechnology
More sections of BBLG: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks